术中置入施源器近距离放疗快速完成保乳治疗的长期结局:一项前瞻性登记数据分析
基于前瞻性登记数据,223例pTis-T2、pN0/pN1mic乳腺癌患者接受术中置入施源器近距离放疗(ABB),中位治疗时间含手术共7天,处方剂量为32 Gy/8次每日两次、34 Gy/10次每日两次或21 Gy/3次每日一次。中位随访63个月,5年同侧乳腺肿瘤无复发生存率为92.2%,绝经后、BMI<30 kg/m2和内分泌治疗依从性与更优的同侧乳腺肿瘤无复发生存率相关。
要点
- 中位随访63个月,5年同侧乳腺肿瘤无复发生存率92.2%,无病生存率91.1%。
- 绝经后、BMI<30 kg/m2和内分泌治疗依从者5年同侧乳腺肿瘤无复发生存率更高。
- 同侧乳腺肿瘤无复发生存率在不同剂量方案间无差异。
核心结论
- 绝经后状态、BMI<30 kg/m2和内分泌治疗依从性预测更优的同侧乳腺肿瘤无复发生存率。
- 结果强调应仔细选择适合ABB的患者并鼓励内分泌治疗依从。
研究设计与样本
- 前瞻性登记数据分析,纳入223例pTis-T2、pN0/pN1mic乳腺癌患者接受术中置入施源器近距离放疗(ABB)。
- 中位治疗时间含手术和ABB共7天,处方剂量为32 Gy/8次每日两次(n=25)、34 Gy/10次每日两次(n=99)和21 Gy/3次每日一次(n=99)。
主要发现
- 218/223例患者为激素受体阳性肿瘤,其中38例(17.0%)为Tis,185例(83.0%)为浸润性癌。
- 中位随访63个月,19例(8.5%)复发,其中17例(7.6%)为同侧乳腺肿瘤复发。
- 5年同侧乳腺肿瘤无复发生存率和无病生存率分别为92.2%和91.1%。
- 5年同侧乳腺肿瘤无复发生存率在绝经后女性为93.6% vs 非绝经后女性66.4%(p=0.04),BMI<30 kg/m2为97.4% vs BMI≥30 kg/m2 88.1%(p=0.02),内分泌治疗依从为97.5% vs 不依从88.6%(p=0.02)。
- 同侧乳腺肿瘤无复发生存率在不同剂量方案间无差异。
临床怎么用
- 作者认为应仔细选择适合ABB的患者并鼓励内分泌治疗依从。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: To evaluate the long-term outcome of accelerated partial breast irradiation utilizing intraoperatively placed applicator-based brachytherapy (ABB) in early-stage breast cancer. MATERIALS AND METHODS: From our prospective registry, 223 patients with pTis-T2, pN0/pN1mic breast cancer were treated with ABB. The median treatment duration including surgery and ABB was 7 days. The prescribed doses were 32 Gy/8 fx BID (n = 25), 34 Gy/10 fx BID (n = 99), and 21 Gy/3 fx QD (n = 99). Endocrine therapy (ET) adherence was defined as completion of planned ET or ≥ 80% of the follow-up (FU) period. Cumulative incidence of ipsilateral breast tumor recurrence (IBTR) was estimated and influencing factors for IBTR-free survival rate (IBTRFS) were analyzed. RESULTS: 218/223 patients had hormone receptor-positive tumors, including 38 (17.0%) with Tis and 185 (83.0%) with invasive cancer. After a median FU of 63 months, 19 (8.5%) patients had recurrence [17 (7.6%) with an IBTR]. Rates of 5-year IBTRFS and DFS were 92.2% and 91.1%, respectively. The 5-year IBTRFS rates were significantly higher for post-menopausal women (93.6% vs. 66.4%, p = 0.04), BMI < 30 kg/m2 (97.4% vs. 88.1%, p = 0.02), and ET-adherence (97.5% vs. 88.6%, p = 0.02). IBTRFS did not differ with dose regimens. CONCLUSIONS: Postmenopausal status, BMI < 30 kg/m2, and ET- adherence predicted favorable IBTRFS. Our results highlight the importance of careful patient selection for ABB and encouragement of ET compliance.
引用
- Kim H, Hieken TJ, Abraha F, et al. Long-term outcomes of intraoperatively-placed applicator brachytherapy for rapid completion of breast conserving treatment: An analysis of a prospective registry data. Clin Transl Radiat Oncol. 2023. PMID: 37251618. doi:10.1016/j.ctro.2023.100639
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。